Malaria Vaccines: Pfs28-rEPA/ALHYDROGEL

pfs 28已被证明可以诱导抗体，阻止蚊子体内寄生虫的发育。 然而，该蛋白质的免疫原性差。 受增加Pfs 25免疫原性的缀合策略的成功启发，我们还开发了将Pfs 28缀合至rEPA的方法。 评价了各种缀合化学和方法的最佳免疫原性和稳健的缀合过程。 表征Pfs 28-rEPA的生物化学性质，并在动物中评价缀合物的免疫原性。 测试由缀合物疫苗诱导的免疫血清阻断蚊子中寄生虫发育的能力。 与此同时，我们还将Pvs 28（间日疟原虫寄生虫中的动合子表面蛋白，由Pfs 28的orthorlog基因编码）与rEPA结合。 Pvs 28-rEPA将与Pfs 25-rEPA组合为双组分疫苗，以扩大免疫覆盖范围并提高疫苗效力。

Pfs28 has been shown to induce antibodies that can block parasite development in mosquitoes. However, the protein is poorly immunogenic. Inspired by success of the conjugation stratagy for increasing the immunogenicity of the Pfs25, we also developed a process to conjugate Pfs28 to rEPA. Various conjugation chemistries and methods were evaluated for the optimal immunogenicity and the robust conjugation processes. The biochemical properties of the Pfs28-rEPA were characterized and the conjugates were evaluated in animals for their immunogenicity. The immune sera induced by the conjugate vaccine were tested for their ability to block parasite development in mosquitoes. In parallel, we are also conjugating Pvs28, an ookinete surface protein in Plasmodium vivax parasite and encoded by an orthorlog gene of Pfs28, to rEPA. The Pvs28-rEPA will be combined with Pfs25-rEPA as a two-component vaccine to broaden the immune coverage and increase the vaccine efficacy.